Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in three upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference on November 19th at 10:20 a.m. ET, the 7th Annual Evercore HealthCONx Conference on December 3rd at 2:10 p.m. ET, and Citi's 2024 Global Healthcare Conference on December 4th. Interested parties can access webcast links and additional information through Mirum's corporate website under the Investors and Media section.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences:

• Stifel 2024 Healthcare Conference on Tuesday, November 19^th
  • Company presentation - Tuesday, November 19^th starting at 10:20 a.m. ET

• 7th Annual Evercore HealthCONx Conference on Tuesday, December 3^rd
  • Company presentation - Tuesday, December 3^rd starting at 2:10 p.m. ET

• Citi’s 2024 Global Healthcare Conference on Wednesday, December 4^th

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum is also initiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Lastly, chenodiol, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023. Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the U.S.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107101895/en/

Investors:

Andrew McKibben

ir@mirumpharma.com



Media:

Erin Murphy

media@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When is Mirum Pharmaceuticals (MIRM) presenting at the Stifel 2024 Healthcare Conference?

Mirum Pharmaceuticals (MIRM) is presenting at the Stifel 2024 Healthcare Conference on Tuesday, November 19th at 10:20 a.m. ET.

Which investor conferences will Mirum Pharmaceuticals (MIRM) attend in late 2024?

Mirum Pharmaceuticals will attend three conferences: Stifel 2024 Healthcare Conference (November 19th), Evercore HealthCONx Conference (December 3rd), and Citi's Global Healthcare Conference (December 4th).

What time is Mirum Pharmaceuticals' (MIRM) presentation at the Evercore HealthCONx Conference?

Mirum Pharmaceuticals will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3rd at 2:10 p.m. ET.

Where can investors find webcast links for Mirum Pharmaceuticals' (MIRM) conference presentations?

Investors can find webcast links and additional information in the Investors and Media section of Mirum Pharmaceuticals' corporate website.